C-OPTIMISE: Certolizumab Pegol Therapy Withdrawal in Patients With axSpA Associated With Increased Disease Activity in Patients Without Flares

June 2-5, 2021; Virtual
Even without flare, withdrawal of CZP associated with increased ASDAS, CRP, BASDAI, and fecal calprotectin.
Format: Microsoft PowerPoint (.ppt)
File Size: 327 KB
Released: August 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

From Clinical Care Options (CCO), new data in managing axial psoriatic arthritis and axial spondyloarthritis from EULAR 2021

Atul Deodhar, MD Philip Mease, MD, MACR Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: September 2, 2021 Expired: September 1, 2022

Video from Clinical Care Options (CCO) featuring expert insights into the whole-patient approach including treatment selection, common comorbidities, and coordination of care for patients with PsO/PsA.

April W. Armstrong, MD, MPH Philip Mease, MD, MACR Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: August 27, 2021 Expired: August 26, 2022

Dr. Atul Deodhar discusses the latest clinically relevant data on drug-free remission in axSpA, MRI for axSpA diagnosis, vaccination for COVID-19 in patients with autoimmune inflammatory rheumatic diseases from Clinical Care Options (CCO).

Atul Deodhar, MD Released: August 26, 2021

Clinical Care Options (CCO) faculty Dr. April Armstrong and Dr. Philip Mease discuss problem of access to dermatologists and rheumatologists experienced by patients with PsO and PsA and potential solutions

April W. Armstrong, MD, MPH Philip Mease, MD, MACR Released: August 20, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue